前言：在台灣C型肝炎的盛行率約為2-5%。C型肝炎治療目前以pegylated interferon與ribavirin的合併使用為主，Zepatier (Elbasvir+Grazoprevir)對慢性C型肝炎病患的實際療效與藥物使用評估的數據是有限的。目的：我們旨在評估在HCV患者中Zepatier的臨床表現。方法：:研究納入16例接受Zepatier治療慢性C肝炎或HCV相關性肝硬化代償性患者。比較Zepatier治療之前(基線)及8周治療結束(End of treatment, EOT)與8周治療結束後12週(Follow-up 12)持久性病毒反應（Sustained virologic response，SVR12）和血液生化檢查。藉此研究SVR12和生化檢查隨治療時間的變化。結果：患者於基線和EOT之間(p<0.05)以及EOT和治療結束後的12週(p<0.01)之間的GOT和GPT含量存在顯著差異。在基線和EOT治療結束後的12週，血清白蛋白水平發現顯著升高(p<0.01)。而接受8周治療的患者的總體SVR率為100％。但在基線和Follow-up 12之間則總膽紅素(Total bilirubin)顯著減少(p<0.05)。結語：慢性HCV患者接受八周Zepatier治療具有良好耐受性及導致較高的SVR12。

Background: The prevalence of chronic hepatitis C is 2% to 5% in Taiwan. The optimal therapeutic regimen for hepatitis C is pegylated interferon in combination with ribavirin. The data regarding the real-world effectiveness and drug use evaluation of Zepatier (Elbasvir+Grazoprevir) for patients with chronic hepatitis C virus (HCV) infection were limited in Taiwan. Objective: We aimed to evaluate the clinical performance of Zepatier in HCV patient. Methods: 16 patients with chronic hepatitis C or HCV-related compensated cirrhosis who were treated with Zepatier were included in the study. Sustained virologic response at 12 weeks after the end of therapy (SVR12) and the biochemical examinations were measured before Zepatier treatment (Baseline), at the end of treatment (EOT, 8weeks), and at 12 weeks after EOT (Follow-up 12). The changes over time in the SVR12 and biochemical examinations were investigated. Results: The study included differences in GOT and GPT levels were seen between Baseline and EOT ( p < 0.01) and between EOT and Follow-up 12 ( p < 0.01). There was significant difference in serum albumin levels in Baseline and Follow-up 12 ( p <0.01). Moreover, the overall SVR rate was 100% in patients receiving 8 weeks of treatment. The SVR12 rates were comparable regardless of baseline characteristics or week 8 and Follow-up 12 viral decline. But a significant decrease in Total bilirubin was seen between Baseline and Follow-up 12 ( p < 0.05). Conclusion: Eight-week Zepatier was well tolerated and led to a high SVR12 rate in treatment patients with chronic HCV infection.